Literature DB >> 24166860

Ethical considerations surrounding survival benefit-based liver allocation.

Eric J Keller1, Paul Y Kwo, Paul R Helft.   

Abstract

The disparity between the demand for and supply of donor livers has continued to grow over the last 2 decades, and this has placed greater weight on the need for efficient and effective liver allocation. Although the use of extended criteria donors has shown great potential, it remains unregulated. A survival benefit-based model was recently proposed to answer calls to increase efficiency and reduce futile transplants. However, it was previously determined that the current allocation system was not in need of modification and that instead geographic disparities should be addressed. In contrast, we believe that there is a significant need to replace the current allocation system and complement efforts to improve donor liver distribution. We illustrate this need first by identifying major ethical concerns shaping liver allocation and then by using these concerns to identify strengths and shortcomings of the Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease system and a survival benefit-based model. The latter model is a promising means of improving liver allocation: it incorporates a greater number of ethical principles, uses a sophisticated statistical model to increase efficiency and reduce waste, minimizes bias, and parallels developments in the allocation of other organs. However, it remains limited in its posttransplant predictive accuracy and may raise potential issues regarding informed consent. In addition, the proposed model fails to include quality-of-life concerns and prioritize younger patients. We feel that it is time to take the next steps toward better liver allocation not only through reductions in geographic disparities but also through the adoption of a model better equipped to balance the many ethical concerns shaping organ allocation. Thus, we support the development of a similar model with suggested amendments.
© 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 24166860     DOI: 10.1002/lt.23780

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection.

Authors:  Fabio Bagante; Gaya Spolverato; Andrea Ruzzenente; Ana Wilson; Faiz Gani; Simone Conci; Alexander Yahanda; Tommaso Campagnaro; Alfredo Guglielmi; Timothy M Pawlik
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

2.  Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Authors:  Willscott E Naugler; Barry Schlansky; Susan L Orloff
Journal:  Hepat Oncol       Date:  2014-03-20

3.  Impact of Race and Ethnicity on Outcomes for Children Waitlisted for Pediatric Liver Transplantation.

Authors:  Douglas B Mogul; Xun Luo; Eric K Chow; Allan B Massie; Tanjala S Purnell; Kathleen B Schwarz; Andrew M Cameron; John F P Bridges; Dorry L Segev
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

Review 4.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

5.  Benefit in liver transplantation: a survey among medical staff, patients, medical students and non-medical university staff and students.

Authors:  Christine Englschalk; Daniela Eser; Ralf J Jox; Alexander Gerbes; Lorenz Frey; Derek A Dubay; Martin Angele; Manfred Stangl; Bruno Meiser; Jens Werner; Markus Guba
Journal:  BMC Med Ethics       Date:  2018-02-12       Impact factor: 2.652

6.  Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts.

Authors:  Matteo Ravaioli; Maurizio Baldassare; Francesco Vasuri; Gianandrea Pasquinelli; Maristella Laggetta; Sabrina Valente; Vanessa De Pace; Flavia Neri; Antonio Siniscalchi; Chiara Zanfi; Valentina R Bertuzzo; Paolo Caraceni; Davide Trerè; Pasquale Longobardi; Antonio D Pinna
Journal:  Ann Transplant       Date:  2018-01-12       Impact factor: 1.530

Review 7.  Should living donor liver transplantation be an option when deceased donation is not?

Authors:  Sarah R Lieber; Thomas D Schiano; Rosamond Rhodes
Journal:  J Hepatol       Date:  2017-11-01       Impact factor: 30.083

8.  Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?

Authors:  Manhal Izzy; Sophoclis Alexopoulos; Alexandra Shingina
Journal:  JHEP Rep       Date:  2021-04-22

Review 9.  Surgical management of hepatocellular carcinoma-Western versus Eastern attitude.

Authors:  Flavia Neri; Lorenzo Maroni; Matteo Ravaioli
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.